NPHLA Daily
NPHLA Daily
Tuesday, October 20, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 7 trial updates
NPHLA tracked 7 new official records on this desk today: 7 trial updates. First: New trial registered: AMPLIFY-2 (A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes)
Metabolic signal
New trial registered: S-CUD (Semaglutide for the Treatment of Cannabis Use Disorder)
Phase 2, Massachusetts General Hospital. Conditions: Cannabis Use Disorder; Cue-reactivity. Interventions: semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
Regulatory signal
What changed today in Regulatory: 1 proposed rule
NPHLA tracked 1 new official record on this desk today: 1 proposed rule. First: Proposed rule published: Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026.
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 new study, 1 trial update
NPHLA tracked 2 new official records on this desk today: 1 new study, 1 trial update. First: New research in International journal of nanomedicine: “Exosomes Derived from Sea Cucumbers in Indonesian Marine for Anti-Aging and Skin Regeneration”.
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in International journal of pediatric otorhinolaryngology: “Implementation and early outcomes of AI-powered ambient documentation in pediatric otolaryngology practice”.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 7 trial updates
- What changed today in Aesthetics & Longevity: 1 new study, 1 trial update
- What changed today in Regulatory: 1 proposed rule
- What changed today in AI & Technology: 1 new study
- New trial registered: S-CUD (Semaglutide for the Treatment of Cannabis Use Disorder) (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.